"Combined novel ultra-diluted bioactive formulation enhances Sodium Stibogluconate efficacy via T cell-mediated cytokine modulation in experimental visceral leishmaniasis".
Abstract
Background
Visceral leishmaniasis (VL), caused by Leishmania donovani, is a life-threatening neglected tropical disease that continues to pose a major public health challenge in endemic regions. Although sodium stibogluconate (SSG) has been widely used for VL treatment, its therapeutic efficacy has been undermined by increasing drug resistance and dose-related toxicity. Immunomodulatory interventions, including ultra-diluted Leishmania antigen (udLA), may enhance host defense mechanisms and improve treatment outcomes.
Objective
This study aimed to evaluate the antileishmanial efficacy, immunomodulatory effects and safety of SSG in combination with udLA in a BALB/c mouse model of VL.
Methods
BALB/c mice infected with L. donovani were treated with SSG (low and high dose), udLA alone, or combinations of SSG and udLA. Parasite burden was quantified using Leishman-Donovan Units and quantitative PCR. Immunological assessments included analysis of CD4+ and CD8+ T-cell populations, reactive oxygen species (ROS), nitric oxide (NO) production, cytokine profiling and expression of iNOS and NF-κB genes. Hepatic and renal function markers were evaluated to determine treatment-associated toxicity.
Results
All treatment groups showed significant reductions in parasite burden compared with infected controls; however, the SSG+udLA combination achieved the greatest protection. Combination therapy significantly enhanced host immune responses, evidenced by increased CD4+ and CD8+ T-cell activation, elevated ROS and NO production and upregulated iNOS and NF-κB expression. Cytokine analysis demonstrated a strong Th1-skewed immune response, characterized by increased IFN-γ, TNF-α and IL-17 levels and reduced IL-10, IL-13 and IL-27 expression. Furthermore, combination therapy using udLA and SSG (low dose) normalized liver and kidney functions however, at higher dose of SSG liver toxicity was reported.
Conclusion
The SSG-udLA combination represents a promising adjunctive therapeutic strategy for VL, providing enhanced antileishmanial efficacy, potent immunomodulation and improved safety over conventional monotherapy.